Lilly’s Claims of Mounjaro Trademark Infringement Get ITC Investigation
The U.S. International Trade Commission (USITC) has voted to investigate 11 online pharmacies that are importing, selling and distributing products purported to contain the active ingredient in Eli Lilly’s blockbuster glucagon-like peptide-1 (GLP-1) receptor agonist Mounjaro (tirzepatide).
The investigation is based on a complaint filed by Lilly on Oct. 19. The USITC said in its announcement that “the complainant requests that the USITC issue a general exclusion order or, in the alternative, a limited exclusion order, and cease and desist orders.”
An administrative law judge (ALJ) will be assigned to the case and will hold an evidentiary hearing. The ALJ’s initial determination will be reviewed by the Commission. Any orders will be effective when issued and become final 60 days after issuance, unless disapproved for policy reasons by the U.S. Trade Representative within that 60-day period.
Read the ITC complaint here.
To read the whole story, click here to subscribe.